

### Rexahn: Developing Oncology and CNS Drugs That Treat Disease in Fundamentally New Ways

- ◆ Rexahn Pharmaceuticals, Inc. is a clinical stage drug company developing oncology and CNS drugs that are potentially best in class and may achieve disease modification.
- ◆ Proprietary drug development platform and scientific expertise capable of producing drugs that address multiple disease indications, and may establish new standards of care.
- ◆ Rexahn currently has three drug candidates in Phase II clinical trials - Archexin™, Serdaxin™ and Zoraxel™ - all potential best-in-class therapeutics.

### Opportunity to Invest in Best-in-Class Cancer and CNS Medicines

- ◆ **Three potential best-in-class drugs in Phase II clinical trials**
  - **Archexin** inhibits a cancer cell signaling protein called Akt, which is involved in cancer cell growth, survival, angiogenesis, and drug resistance – the only cancer drug with potent, selective downregulation of native and activated forms of Akt.
  - **Serdaxin** is a dual enhancer of serotonin and dopamine levels in the brain. It has shown in preclinical studies the potential to treat multiple CNS illnesses including depression, anxiety, and neurodegenerative disorders such as Parkinson's disease. Serdaxin has demonstrated neuroprotective activity, and may have the unique ability to slow progression of some CNS diseases.
  - **Zoraxel** is a centrally acting drug designed to treat sexual dysfunction and address high unmet needs in erectile dysfunction (ED). It is being developed as a potential new standard of care therapeutic that focuses on the CNS and the dual role of dopamine and serotonin neurotransmitters in the brain in phases of sexual functioning, arousal and release. In a Phase IIa clinical study, ED patients treated with Zoraxel demonstrated improved erectile function as measured by changes over IIEF baseline score within the 8-week treatment period.
- ◆ **Rich portfolio of pre-clinical compounds**
  - Developing a world-class oncology therapeutics franchise that spans the major classes of cancer drugs, including molecular targeted therapies, signal transduction inhibitors, and nanomedicines.
- ◆ **Proprietary drug discovery platform**
  - Proprietary nano-medicines and multi-target aimed ligands platform technologies strengthen our oncology portfolio, with cancer drugs that have potentially greater efficacy and quality of life benefits.
- ◆ **Potential Fast Track to market**
  - Developing orphan drugs allows Rexahn to maximize benefits of the Orphan Drug Act, such as fast track review by the FDA, market exclusivity, and tax benefits.

### R&D Pipeline

Drug Candidate	Target Indication(s)	R&D Status	Remarks
<b>Archexin™</b>	Pancreatic Cancer* Renal Cell Carcinoma (RCC)* Other solid tumors	Phase II Phase II Planned	First-in-class, potent Akt inhibitor FDA orphan drug designation in 5 cancers Ovarian*, Prostate, and Lung cancers
<b>Serdaxin™</b>	Major Depressive Disorder Parkinson's Disease Anxiety Disorders	Phase II Planned Planned	Dual serotonin and dopamine enhancer Potential CNS market leader Unique advantages and target profile
<b>Zoraxel™</b>	Erectile Dysfunction (ED)	Phase II	Centrally acting for sexual dysfunction (SD) Clinical program planned for female SD
<b>Oncology preclinical compounds:</b>			
RX-0183	Cancers of: Colon, Lung	Preclinical	Akt and c-Fos downregulation
RX-0047	Prostate, Lung, Breast	Preclinical	First-in-class HIF-1 inhibitor
RX-5902	Renal, Pancreas, Melanoma	Preclinical**	Microtubule inhibitor, cytotoxic
RX-3117	Colon, Lung	Preclinical**	Anti-metabolite nucleoside, cytotoxic
HPMA nanomedicines	Lung, Breast, Pancreas	Preclinical	Nano- polymer conjugated cancer drugs, HPMA-gemcitabine and HPMA-docetaxel

\*FDA Orphan drug designation, also includes glioblastoma and stomach cancers

\*\*IND-enabling studies in progress

## Clinical Stage Pipeline Summary

### Archexin™

Archexin is a first-in-class, potent and selective inhibitor of the Akt protein kinase. Akt is involved in cancer cell growth and survival, drug resistance, and angiogenesis. Archexin is the first cancer drug compound that inhibits both native and activated forms of Akt. Multiple indications and clinical programs are planned. Archexin has FDA Orphan Drug designation in five cancers, and is in Phase II clinical trials for treating pancreatic cancer. The Phase IIa study is designed as a single arm, open label, dose-ranging study conducted at US and India global sites, and will assess safety and preliminary efficacy of Archexin administered in combination with gemcitabine. Study endpoints include overall survival and tumor response, biomarkers and quality of life.

### Serdaxin™

Serdaxin is a potential market leading CNS therapeutic for treatment of depression, anxiety, and mood disorders; and neurodegenerative disorders such as Parkinson's disease (PD) or Alzheimer's disease. Serdaxin has demonstrated neuroprotective activity in preclinical studies of seizure-induced neurotoxicity and PD disease models. Serdaxin has well-established and extensive safety in humans, and appears to lack the serious side effects, cognitive deficit, or motor impairment that are associated with existing drugs.

### Zoraxel™

Zoraxel is being developed as an immediate release tablet and has demonstrated excellent safety in humans, different from the current PDE-5 inhibitor standard of care for ED. Zoraxel has a centrally acting mechanism designed to regulate CNS-based phases of sexual function, whereas PDE-5 inhibitors work in peripheral blood vessels only. In animal model studies, Zoraxel significantly improved function in three key phases of sexual activity, i.e. arousal, erection, and release. Phase IIa studies are completed, with preliminary data expected Q2 2009.

## Company Milestones

### 2008

- Rexahn Pharmaceuticals, Inc. Shares traded on the American Stock Exchange under the symbol RNN, currently NYSE Amex: RNN
- Selected as a Russell 3000® Company and added to the widely benchmarked Russell Index
- Initiated Zoraxel Phase IIa Double-blind, Placebo Controlled, Multi-center U.S. Trial
- US Patents Issued for Rexahn Cancer Portfolio, RX-0183 and RX-3117 Compounds
- Announced formation of Oncology Scientific Advisory Board (SAB) for clinical development planning and strategy for Archexin

### 2009

- Initiated Archexin Phase IIa Pancreatic Cancer Clinical Trial
- Rexahn Reported Positive Preliminary Findings for Zoraxel PhIIa Clinical Trial
- Rexahn Reported Positive Preliminary Findings for Serdaxin PhIIa Clinical Trial
- Rexahn Raised \$8 in Registered Direct Offering of Common Stock and Warrants to US Institutional Investors
- Rexahn Signed Development and Commercialization Agreement with Teva Pharmaceutical Industries for Novel Anti-cancer Compound

## Experienced Management Team

Rexahn's executive team has over 50 years of combined leadership in the biopharmaceutical industry, with experience in research, development, and commercialization of drugs to address diseases with high unmet needs.

### Chang H. Ahn, Ph.D., Chairman and CEO

Dr. Ahn is an internationally recognized drug development expert in the therapeutic areas of cancer and other life-threatening diseases. He has over 20 years of scientific experience in pharmacology and biotechnology fields. Prior to founding Rexahn, he held dual positions as both Expert Regulatory Officer and Laboratory Chief at the FDA Center for Drug Evaluation and Research.

### Rick Soni, MBA, President & Chief Operating Officer

Mr. Soni has held several leadership and executive positions throughout his 25-year career in the pharmaceutical industry. He has extensive U.S. and international experience in product commercialization, and pharmaceutical sales, marketing, new product planning, and business development. Prior to joining Rexahn, Rick worked at Otsuka Pharmaceuticals for 10 years in corporate and business development roles of increasing responsibility, and in sales and marketing at Novartis and Schering-Plough Corp.

### Tae Heum (Ted) Jeong, M.S., Chief Financial Officer

Mr. Jeong oversees all aspects of finance, accounting, operations, and Sarbanes-Oxley regulatory compliance reporting for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn's 2008 listing on the American Stock Exchange (AMEX). Ted has extensive experience in venture capital, and spent six years as a Senior Investment Manager at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team.

### Rexahn Pharmaceuticals, Inc.

15245 Shady Grove Road, Suite 455  
Rockville, MD 20850

[www.rexahn.com](http://www.rexahn.com)

ir@rexahn.com  
240-268-5300

### Investor Relations Contact

KCSA Strategic Communications  
880 Third Avenue  
New York, NY 10022

Jeffrey Goldberger/Yemi Rose  
212-896-1249/212-896-1233  
[jgoldberger@kcsa.com](mailto:jgoldberger@kcsa.com)  
[yrose@kcsa.com](mailto:yrose@kcsa.com)